Answers are grounded in this paper and cite their sources.
Highlights mechanisms of diabetic cardiomyopathy and the targeted actions of SGLT2 inhibitors, indicating new approaches to treat myocardial dysfunction beyond hypertension and ischemia.
Diabetic cardiomyopathy (DCM) is myocardial contractile dysfunction due to the clustered effects of left ventricular hypertrophy, fetal gene reactivation and lipid accumulation in cardiomyocytes. Structural and functional abnormalities of the myocardium, beyond the elicitation of ischemia or hypertension, have been emphasised and called diabetic cardiomyopathy
No takes yet. Share an insight, caveat, or question.
Chatterjee et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: